Undisclosed Programs

About johnson-and-johnson-innovative-medicine

Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.

About johnson-and-johnson-innovative-medicine

Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.

About johnson-and-johnson-innovative-medicine

Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.

About johnson-and-johnson-innovative-medicine

Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.

About johnson-and-johnson-innovative-medicine

Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.

About Juvena Therapeutics

Juvena Therapeutics is a private, preclinical-stage biotech founded in 2018 and headquartered in Redwood City, California. The company has developed a proprietary AI-powered platform to systematically map the therapeutic potential of secreted proteins and engineer them into biologics aimed at restoring tissue homeostasis. Its lead program, JUV-161 for Myotonic Dystrophy Type 1, has received FDA Orphan Drug Designation and entered first-in-human trials in 2025, supported by a significant research collaboration with Eli Lilly. Juvena is targeting a broad range of degenerative conditions associated with unhealthy aging.

About G3 Therapeutics

G3 Therapeutics is a private, pre-clinical stage biotech employing a human genetics-first approach to drug discovery. The company's core strategy involves sequencing the entire human genome in thousands of individuals and linking genetic variants to disease phenotypes to identify high-confidence therapeutic targets. This data-driven platform aims to reverse the traditional drug development process, starting with human validation to increase the probability of clinical success. While the company has identified multiple novel candidates, its pipeline appears to be in the early discovery and in-vitro stages, indicating a focus on platform validation and asset generation.

About MicuRx Pharmaceuticals

MicuRx Pharmaceuticals is a clinical-stage biotech company pioneering novel antibiotics to combat the global crisis of antimicrobial resistance (AMR). Its pipeline is led by late-stage candidates targeting multidrug-resistant Gram-positive bacteria like MRSA and novel programs against challenging Gram-negative and non-tuberculous mycobacterial (NTM) infections. With a dual operational base in China and the U.S., the company is strategically positioned to address critical public health threats in major markets while navigating the complex development and commercial pathways for anti-infectives.

About Scenic Biotech

Scenic Biotech, founded in 2017, is a private, preclinical-stage biotech developing a novel class of therapeutics based on genetic modifiers. The company's core innovation is its proprietary Cell-Seq discovery platform, which identifies 'hidden disease protection factors' within the genome to rebalance disease pathways, rather than directly correcting the primary genetic defect. This approach has generated a wholly-owned pipeline of small molecule programs and attracted strategic collaborations with major pharmaceutical partners like Alnylam, Bristol Myers Squibb, and Genentech. Scenic is positioned at the forefront of a new therapeutic paradigm with potential applications across a range of severe genetic conditions.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals is on a mission to develop life-changing therapies by targeting C3, the central node of the complement cascade. The company has achieved a significant milestone with three regulatory approvals in four years, validating its platform and establishing commercial capabilities. Its strategy focuses on expanding the reach of its approved C3 inhibitor, pegcetacoplan, into new indications and geographies while advancing a pipeline of novel therapies for rare, retinal, and neurological diseases.

Therapeutic Areas

Other Alzheimer's Disease Drugs